AI Terminal
Apontis Pharma AG
Earnings Release • Nov 8, 2023
725_rns_2023-11-08_82e9c9d6-d6c6-4280-9fec-746f5a97aca2.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 8 November 2023 20:00
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
APONTIS PHARMA AG / Key word(s): Strategic Company Decision/Restructure of Company
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
08-Nov-2023 / 20:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
Monheim am Rhein, 8 November 2023 . APONTIS PHARMA AG („ Company “, Ticker APPH / ISIN DE000A3CMGM5 ) today based on the nine-month figures of the current financial year announces a new forecast for 2023. Accordingly, the Company expects revenues of EUR 36.1 million and EBITDA before restructuring expenses of EUR -8.6 million in the 2023 financial year.
In order to return to a profitable growth path, the Company has also adopted the announced program to increase operational performance and efficiency and presented it to the works council. The objective is to achieve significant savings by reducing personnel while at the same time increasing the effectiveness of sales and marketing. The number of jobs to be reduced is currently being negotiated with the works council. For a full financial year, savings of between EUR 6.0 million and EUR 7.0 million are expected. The necessary restructuring expenses are estimated to total between EUR 5.0 million and EUR 8.0 million.
APONTIS PHARMA AG
Investor Relations
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
APONTIS PHARMA press contact
CROSS ALLIANCE communication GmbH
Sven Pauly
T: +49 89 125 09 0330
End of Inside Information
08-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Alfred-Nobel-Str. 10 | |
| 40789 Monheim | |
| Germany | |
| E-mail: | [email protected] |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1768127 |
| End of Announcement | EQS News Service |